Return to List

Study Summary
No. ACOSOGZ6051:.......Rectum......George Chang......Surgical Oncology
.
Study Summary Title
Study Summary
Number:
ACOSOGZ6051
Study Title:A Phase III Prospective Randomized Trial Comparing Laparoscopic-assisted Resection Versus Open Resection for Rectal Cancer
.
Physician New Patient Referral
Name:George ChangPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Surgical OncologyReferring MD
Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-563-1875
Contact us about clinical trials
.
General Information
Disease Group:RectumSupported By:American College of Surgeons Oncology Group
Phase of Study:Phase IIIReturn
Visit:
Return day 3, week 1-2, week 4-6, then 3, 6, 9, 12, 18 and 24 months. Then
yearly up to year 5.
Treatment
Agents:
Laparoscopic Surgery
Surgical Procedure
Home Care:N/A
Treatment Loc:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated
Length of Stay
in Houston:
N/A
Description/
Intervention:
The goal of this clinical research study is to compare 2 types of surgery
currently used for rectal cancer. The 2 types of surgery are called
laparoscopic-assisted rectal resection (LARR) and open laparotomy rectal
resection (OLRR).

Researchers will compare the safety and effectiveness of the surgeries
(including the doctors' ability to remove the entire tumor, the doctor's
ability to remove the right amount of surrounding tissue, and the amount of
blood lost during surgery). Your recovery from surgery in the hospital will be
monitored, including the amount of pain medication you need, the length of your
hospital stay, and the nature of any surgical complications (problems). Your
overall recovery from surgery, general quality of life, sexual function, and
bowel function will be studied. Researchers will also check to find out if the
cancer comes back in the pelvis or other parts of the body.
.
Study Objectives / Outcomes
Primary Objective
To test the hypothesis that laparoscopic-assisted resection for rectal cancer is not inferior to open rectal resection, based on a composite primary endpoint of oncologic factors which are indicative of a safe and feasible operation.

Changes to Primary Endpoint Oncologic Parameters in Amendment 4

Distal Margin
The current standard of care for all Stage II and III rectal cancer patients is neoadjuvant therapy. In the setting of neoadjuvant therapy, the clinical implications of a close distal margin compared to a negative distal margin are minor. Also, efforts by surgeons to minimize the distance from the distal margin to the tumor in reconstructive procedures have not resulted in an increase in local recurrence. However, true positivity of a distal margin is clearly an undesirable outcome. Therefore, the presence of a negative distal margin (as opposed to a distal margin of a certain distance from the tumor) as a success indicator is preferable and warranted as an endpoint.

Completeness of TME
Combining complete and nearly complete TME categories is based on emerging data that demonstrates that the incidence of (y)pCRM < 1 mm is the same for complete and nearly complete (14.6% and 11%, respectively) but significantly greater (28.2%) (p<0.004) for incomplete. In a pooled analysis of the MRC CR07 and NCIC-CTG CO16 trials, local recurrence rates were nearly the same for complete and nearly complete TME (4% and 7%, respectively), but 13% for incomplete.

The definitions of complete TME and nearly complete TME are subjective. Conversely the distinction between incomplete TME and complete or nearly complete TME is not subtle. The majority of the violations of the mesentery are less than 5 mm, which is usually caused by traction injury rather than cancer surgery violations. The patho-physiological implications of the small encroachment are negligible since there is no tissue left in the pelvis because of the encroachment. For these reasons, an endpoint for surgical success that includes both complete and nearly complete TME (rather than just complete TME) is appropriate.

Revised primary endpoint oncologic parameters:
  • Circumferential margin > 1 mm
  • Negative distal margin
  • Completeness of TME
      o A complete TME is defined as a rectal resection specimen that has an intact mesorectum and covering peritoneal envelope all the way to the level of rectal transection with no coning in of the mesorectum above the point of transection. The surface of the peritoneal covering should be smooth and shiny with no defects exposing the underlying fat.

      o A nearly complete TME is defined as a rectal resection specimen where the mesentery is all present, without coning or missing fat. A < 5 mm deep defect may be present in the envelope covering the mesenteric fat caused either by a wayward incision or traction injury during extraction of the TME specimen through a small extraction site.

A patient will be considered to have a successful resection on either arm if and only if all oncologic
parameters are satisfied. Based on historical data, we expect the rate of successful resection for the
parameters for standard open resection to be 90% for the oncologic parameters. We will accept a 6%
decrement from the successful resection rate of the open (laparotomy) arm of the study to be considered noninferior.

Secondary Objectives
  • To assess patient-related benefit of laparoscopic-assisted resection for rectal cancer vs. open
rectal resection (blood loss, length of stay, pain medicine utilization)
  • To assess disease free survival and local pelvic recurrence at two years.
  • To assess quality of life, sexual function, bowel and stoma function at scheduled time points
throughout the trial.
.
Study Status Information
Study Activation / Registration Date:11/12/2008
IRB Review and Approval Date:11/12/2008
Study Type:Phase Iii
Recruitment Status:Open
Projected Accrual:480
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.

Inclusion Criteria:1) Histologic diagnosis of adenocarcinoma of the rectum (less than or equal to 12cm from the anal verge).

2) Completion of pre-operative 5FU-based chemotherapy and/or radiation therapy. Capecitabine may be substituted for 5FU.

3) Age greater than or equal to 18 years.

4) ECOG (Zubrod) Performance Status less than or equal to 2.

5) Body Mass Index (BMI) less than or equal to 34. NOTE: The same value applies to both male and female patients

6) T3N0M0, TanyN1-2M0 disease as determined by pre-neoadjuvant therapy CT scans and pelvic MRI or transrectal ultrasound. Patients with T4 disease extending to circumferential margin of rectum or invading adjacent organs are not eligible.

Exclusion Criteria:1) Patients with T4 disease

2) No evidence of conditions that would preclude use of a laparoscopic approach (e.g., multiple previous major laparotomies, severe adhesions).

3) No systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude surgery. No other severe incapacitating disease, i.e., ASA IV (a patient with severe systemic disease that is a constant threat to life) or ASA V (a moribund patient who is not expected to survive without the operation).

4) Concurrent or previous invasive pelvic malignancy (cervical, uterine and rectal) within five years prior to registration.

5) History of psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements. NOTE: Incompetent patients are not eligible for this trial.

.
Links
Registration Number: NCT00726622
Study Information on Clinical Trials Registry (clinicaltrials.gov)

Other Links:
.
Results


Return to Clinical Trials at M.D. Anderson Cancer Center